Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 26, 2022; 10(21): 7195-7208
Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7195
Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7195
Table 1 Assessment of Crohn’s Disease severity using the CDAI tool[10]
| Liquid stools per 7 d |
| Well-being (scored as 0 = generally well, 1 = slightly under par, 2 = poor, 3 = very poor, 4 = terrible) |
| Abdominal pain (None = 0; Intermediate = 1 or 2; Severe = 3) |
| Abdominal mass |
| Use of anti-diarrheal agents |
| Presence of extra-intestinal complications: |
| Arthritis/arthralgia |
| Iritis or uveitis |
| Skin or mouth lesions |
| Peri-anal disease |
| Other-fistula |
| Fever > 37.8°C (in the past week) |
| Hematocrit value |
| % Deviation from standard body weight |
- Citation: Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S. Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease. World J Clin Cases 2022; 10(21): 7195-7208
- URL: https://www.wjgnet.com/2307-8960/full/v10/i21/7195.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i21.7195